miodrag ignjatovic / iStockphoto.com
18 September 2018Americas
Allergan to acquire medical aesthetics company for $195m
Allergan has revealed plans to buy Bonti, a biotechnology company focused on medical aesthetics, for $195 million.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
6 February 2017 Allergan has completed its acquisition of LifeCell, a Canada-based regenerative medicine company, for $2.9 billion.
Editor's picks
Editor's picks
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
6 February 2017 Allergan has completed its acquisition of LifeCell, a Canada-based regenerative medicine company, for $2.9 billion.
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
6 February 2017 Allergan has completed its acquisition of LifeCell, a Canada-based regenerative medicine company, for $2.9 billion.